Neurocrine biosciences announces initiation of phase 1 clinical study evaluating effects of nbi-1117567 in healthy adults

San diego , may 8, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), today announced the initiation of its phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound nbi-1117567 in healthy adult participants. nbi-1117567 is an investigational, oral, m1/m4 (m1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.
NBIX Ratings Summary
NBIX Quant Ranking